491000 - Livs Med, Inc.

491000 Summary

Medical Devices

Stock Price & Overview

₩34,500 +1,200 (+3.60%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩34,500 ≈ US$25 · Market cap ₩0.9tn (≈ $622m)

491000 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023
Total Revenue	51.2	27.1	17.3
Cost of Revenue	21.7	12.6	7.8
Gross Profit	29.5	14.5	9.5
Selling, General & Administrative	52.2	41.1	33.4
Operating Income	-22.6	-26.5	-23.9
Finance Income	0.6	9.8	0.3
Finance Costs	1.4	8.8	33.6
Pretax Income	-22.9	-25.6	-57.0
Net Income	-22.9	-25.6	-57.0
Total Comprehensive Income	-22.5	-26.6	-57.3

Breakdown ₩ bn	FY2025	FY2024	FY2023
Total Assets	201.9	53.3	60.4
Current Assets	174.9	37.6	52.6
Cash & Cash Equivalents	11.4	16.8	8.0
Inventories	9.8	4.3	3.8
Trade Receivables	31.7	14.8	8.1
Non-current Assets	27.1	15.6	7.8
Property, Plant & Equipment	13.5	6.6	3.1
Intangible Assets	1.7	1.1	0.8
Total Liabilities	21.1	13.7	177.5
Current Liabilities	13.8	8.9	175.6
Non-current Liabilities	7.3	4.7	2.0
Total Equity	180.9	39.6	-117.1
Share Capital	12.3	10.7	8.3
Retained Earnings	-295.9	-273.0	-247.4

Breakdown ₩ bn	FY2025	FY2024	FY2023
Cash from Operating Activities	-34.7	-27.7	-24.7
Cash from Investing Activities	-129.2	26.4	-35.0
Purchase of Property, Plant & Equipment	7.2	4.3	2.3
Cash from Financing Activities	158.4	10.2	52.9
Net Change in Cash	-5.4	8.8	-6.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4
Total Revenue	12.5	10.3	—
Cost of Revenue	7.1	5.8	—
Gross Profit	5.4	4.5	—
Selling, General & Administrative	17.6	12.9	—
Operating Income	-12.2	-8.4	—
Finance Income	1.4	2.7	—
Finance Costs	0.2	0.2	—
Pretax Income	-11.0	-5.9	—
Income Tax Expense	0.0	0.0	—
Net Income	-11.0	-5.9	—
Total Comprehensive Income	-11.7	-7.4	—

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4
Total Assets	187.9	197.8	201.9
Current Assets	117.1	167.5	174.9
Cash & Cash Equivalents	50.5	16.4	11.4
Inventories	14.6	14.2	9.8
Trade Receivables	34.4	33.4	31.7
Non-current Assets	70.8	30.3	27.1
Property, Plant & Equipment	52.5	15.5	13.5
Intangible Assets	2.1	2.0	1.7
Total Liabilities	24.0	23.1	21.1
Current Liabilities	15.0	15.2	13.8
Non-current Liabilities	9.0	7.8	7.3
Total Equity	163.9	174.8	180.9
Share Capital	12.5	12.5	12.3
Retained Earnings	-312.8	-301.8	-295.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4
Cash from Operating Activities	-17.7	-12.9	—
Cash from Investing Activities	52.0	17.7	—
Purchase of Property, Plant & Equipment	31.7	1.7	—
Cash from Financing Activities	-0.2	0.2	—
Net Change in Cash	34.1	5.0	—

Consolidated (CFS), from DART. 3 fiscal years and 3 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

491000 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	51.2	+88.8%	—	—	—
Operating income	-22.6	—	—	—	—
Net income	-22.9	—	—	—	—
EPS	₩-906	—	—	—	—
Operating cash flow	-34.7	—	—	—	—
Shareholders' equity	180.9	+356.7%	—	—	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

491000 Profitability

Ratio	FY2025	FY2024	FY2023
Gross margin	57.7%	53.6%	54.9%
Operating margin	-44.2%	-97.7%	-138.5%
Net margin	-44.7%	-94.3%	-330.2%
Return on equity	-20.7%	—	—
Return on assets	-17.9%	-45.0%	-94.4%
Operating cash flow / revenue	-67.9%	-102.0%	-143.2%
Capex / revenue	14.1%	16.0%	13.3%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 491000

Symbol	Last Price
096530Seegene, Inc.	₩31,900 +1.1%
041830In Body Co., Ltd.	₩61,100 +2.5%
445680Curiox Biosystems Co., Ltd.	₩47,650 -1.5%
458870Seers Co., Ltd.	₩21,350 +3.1%
137310SD Biosensor	₩6,160 -0.3%
377740Bio Note, Inc.	₩4,790 -0.2%
340570T & L Co., Ltd.	₩29,650 +1.2%
099190i-SENS, Inc.	₩16,470 +0.0%
336570WON Tech Co., Ltd.	₩4,905 +0.9%
174900Ab Clon, Inc.	₩21,600 +5.9%

Compare all 13 in Medical Devices

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.